Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients

Clinical Cancer Research

Volumn 3, Issue 8, 1997, Pages 1277-1288

  Albertini, Mark R ^a,c   Hank, Jacquelyn A ^a   Schiller, Joan H ^a   Khorsand, Masoud ^a   Borchert, Agnes A ^a   Gan, Jacek ^a   Bechhofer, Robin ^a   Storer, Barry ^a   Reisfeld, Ralph A ^b   Sondel, Paul M ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC MONOCLONAL ANTIBODY 14.18; GANGLIOSIDE ANTIBODY; MORPHINE; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG HYPERSENSITIVITY; FEMALE; FLU LIKE SYNDROME; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOKINE ACTIVATED KILLER CELL; MALE; MELANOMA; PERICARDIAL EFFUSION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; THORAX PAIN;

ADULT; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED;

EID: 0030756133     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Oppenheim, M. H., and Lotze, M. T. Interleukin-2: solid-tumor therapy. Oncology (Basel), 51: 154-169, 1994.
2. Parkinson, D. H. Enhancement of the antineoplastic activity of interleukin-2. In: M. B. Atkins and J. W. Mier (eds.), Therapeutic Applications of Interleukin-2, pp. 439-454. New York: Marcel Dekker, Inc., 1993.
3. Soiffer, R. J., Chapman, P. B., Murray, C., Williams, L., Unger, P., Collins, H., Houghton, A. N., and Ritz, J. Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma. Clin. Cancer Res., 3: 17-24, 1997.
4. Itoh, K., Platsoucas, D., and Balch, C. M. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas, activation by interleukin-2 and autologous tumor cells and involvement of the T-cell receptor. J. Exp. Med., 168: 1419-1441, 1988.
5. Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., Simpson, C., Carter, C., Bock, S., Schwartzentruber, D., Wei, J. P., and White, D. E. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N. Engl. J. Med., 319: 1676-1680, 1988.
6. Rosenberg, S. A., Yang, J. C., Topalian, S. L., Schwartzentruber, D. J., Weber, J. S., Parkinson, D. R., Seipp, C. A., Einhorn, J. H., and White, D. E. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. J. Am. Med. Assoc., 271: 907-913, 1994.
7. Sosman, J. A., Kohler, P. C., Hank, J. A., Moore, K. H., Bechhofer, R., Storer, B., and Sondel, P. M. Repetitive weekly cycles of IL-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin. J. Natl. Cancer Inst. (Bethesda), 80: 1451-1460, 1988.
8. Hank, J. A., Kohler, P. C., Weil-Hillman, G., Rosenthal, N., Moore, K. H., Storer, B., Minkoff, D., Bradshaw, J., Bechhofer, R., and Sondel, P. M. In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2. Cancer Res., 48: 1965-1971, 1988.
9. Sondel, P. M., Hank, J. A., Kohler, P. C., Chen, B. P., Minkoff, D. Z., and Molenda, J. A. Destruction of autologous human lymphocytes by IL-2 activated cytotoxic cells. J. Immunol., 137: 502-511, 1986.
10. Damle, N. K., Doyle, L. V., Bender, J. R., and Bradley, E. C. IL-2 activated human lymphocytes exhibit enhanced adhesion to normal vascular endothelial cells and cause their lysis. J. Immunol., 138: 1779-1785, 1987.
11. Ettinghausen, S. E., Puri, R. K., and Rosenberg, S. A. Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant IL-2 in mice. J. Natl. Cancer Inst. (Bethesda), 80: 177-188, 1988.
12. Ferradini, L., Mackensen, A., Genevee, C., Bosq, J., Duvillard, P., Avril, M. F., and Hercend, T. Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. J. Clin. Invest., 91: 1183-1190, 1993.
13. Wiebke, E. A., Rosenberg, S. A., and Lotze, M. T. Acute immunologic effects of interleukin-2 therapy in cancer patients: decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigens. J. Clin. Oncol., 9: 1440-1449, 1988.
14. Hank, J. A., Sosman, J. A., Kohler, P. C., Bechhofer, R., Storer, B., and Sondel, P. M. Depressed T cell responses concomitant with increased IL-2 induced responses following in vivo treatment with IL-2. J. Biol. Response Modif., 9: 5-14, 1990.
15. Munn, D. H., and Cheung, N. K. V. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma. Cancer Res., 47: 6600-6605, 1987.
16. Honsik, C. J., Jung, G., and Reisfeld, R. A. LAK cells targeted by monoclonal antibody to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin. Proc. Natl. Acad. Sci. USA, 83: 7893-7897, 1986.
17. Shiloni, E., Eisenthal, A., Sachs, D., and Rosenberg, S. A. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin-2. J. Immunol., 138: 1992-1998, 1987.
18. Mujoo, K., Cheresh, D. A., Yang, H. M., and Reisfeld, R. A. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res., 47: 1098-1104, 1987.
19. D2 antibody 14.18. Cancer Res., 49: 2857-2861, 1989.
20. Saleh, M. N., Khazaeli, M. B., Wheeler, R. H., Allen, L., Tilden, A. B., Grizzle, W., Reisfeld, R. A., Yu, A. L., Gillies, S. D., and LoBuglio, A. F. Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. Hum. Antib. Hybrid., 3: 19-24, 1992.
21. D2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res., 54: 144-149, 1991.
22. Mueller, B. M., Romerdahl, C. A., Gillies, S. D., and Reisfeld, R. A. Enhancement of antibody-dependent cytotoxicity with a chimeric antiGD2 antibody. J. Immunol., 144: 1382-1386, 1990.
23. Goldstein, D., Sosman, J. A., Hank, J. A., Weil-Hillman, G., Moore, K. H., Borchert, R., Storer, B., Kohler, P. C., Levitt, D., and Sondel, P. M. Repetitive weekly cycles of interleukin-2 (IL-2): outpatient treatment with a lower dose of IL-2 maintains heightened non-MHC restricted killer activity. Cancer Res., 49: 6832-6839, 1989.
24. Schlom, J. Monoclonal antibodies in cancer therapy. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Biologic Therapy of Cancer, pp. 507-521. Philadelphia: J. B. Lippincott Co., 1995.
25. 2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. J. Immunother., 15: 29-37, 1994.
26. Albertini, M. R., Gan, J., Jaeger, P., Hank, J. A., Storer, B., Schell, K., Rivest, T., Surfus, J., Reisfeld, R. A., Schiller, J. H., and Sondel, P. M. Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma. J. Immunother., 19: 278-295, 1996.
27. Albertini, M. R., Sosman, J. A., Hank, J. A., Moore, K. H., Borchert, A., Schell, K., Kohler, P. C., Bechhofer, R., Storer, B., and Sondel, P. M. The influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2. Cancer (Phila.), 66: 2457-2464, 1990.
28. Liao, S. K., Horton, L., Flahart, R. E., O'Rear, L., Crumpacker, D., Imbaratto, J. W., Yannelli, J. R., Robinson, R. R., and Oldham, R. K. Binding and functional properties of a mouse-human chimeric monoclonal antibody of the human IgG1 subclass with specificity for human carcinomas. Hum. Antib. Hybrid., 1: 66-76, 1990.
29. Robinson, R. R., Chartier, J., Jr., Chang, C. P., Horwitz, A. H., and Better, M. Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities. Hum. Antib. Hybrid. 2: 84-93, 1991.
30. Pross, H. F., and Maroun, J. A. The standardization of NK cell assays for use in studies of biological response modifiers. J. Immunol. Methods, 68: 235-249, 1984.
31. Hank, J. A., Albertini, M., Wesly, O. H., Schiller, J. H., Borchert, A., Moore, K., Bechhofer, R., Storer, B., Gan, J., Gambacorti, C., Sosman, J., and Sondel, P. M. Clinical and immunological effects of treatment with murine anti-CD3 monoclonal antibody along with interleukin 2 in patients with cancer. Clin. Cancer Res., 1: 481-491, 1995.
32. Murray, J. L., Kleinerman, E. S., Jia, S. F., Rosenblum, M. G., Eton, O., Buzaid, A., Legha, S., Ross, M. I., Thompson, L., Mujoo, K., Tieger, P. T., Saleh, M., Khazaeli, M. B., and Vadhan-Raj, S. Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma. J. Immunother., 19: 206-217, 1996.
33. D2 antibody 14G2a in metastatic melanoma. Cancer Res., 52: 4342-4347, 1992.
34. Khazaeli, M. B., Conry, R. M., and LoBuglio, A. F. Human immune response to monoclonal antibodies. J. Immunother., 15: 42-52, 1994.
35. Kennedy, R. C., Zhou, E. M., Lanford, R. E., Chanh, T. C., and Bona, C. A. Possible role of anti-idiotypic antibodies in the induction of tumor immunity. J. Clin. Invest., 80: 1217-1224, 1987.
36. Albertini, M. R., Hank, J. A., and Sondel, P. M. Strategies for improving antitumor activity utilizing IL-2: preclinical models and analysis of antitumor activity of lymphocytes from patients receiving IL-2. Biotherapy (Dordrecht), 4: 189-198, 1992.
37. Hamilton, W. B., Helling, F., Lloyd, K. O., and Livingston, P. O. Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography. Int. J. Cancer, 53: 566-573, 1993.
38. Tsuchida, T., Saxton, R. E., Morton, D. L., and Irie, R. F. Ganglio-sides of human melanoma. Cancer (Phila.), 63: 1166-1174, 1989.
39. Urmacher, C., Cordon-Cardo, C., and Houghton, A. N. Tissue distribution of GD3 ganglioside detected by mouse monoclonal antibody R24. Am. J. Dermatopathol., 16: 577-581, 1989.
40. D3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. J. Clin. Oncol., 6: 1636-1648, 1988.
41. Harel, W., Shau, H., Hadley, C. G., Morgan, A. C., Jr., Reisfeld, R. A., Cheresh, D. A., and Mitchell, M. S. Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro. Cancer Res., 50: 6311-6315, 1990.
42. Bajorin, D. F., Chapman, P. B., Wong, G., Coit, D. G., Kunicka, J., Dimaggio, J., Cordon-Cardo, C., Urmacher, C., Dantes, L., Templeton, M. A., Liu, J., Oettgen, H. F., and Houghton, A. N. Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma. Cancer Res., 50: 7490-7495, 1990.
43. 2 interleukin-2 fusion protein (ch14.18-IL2). Clin. Cancer Res., 2: 1951-1959, 1996.
44. Becker, J. C., Varki, N., Gillies, S. D., Furukawa, K., and Reisfeld, R. A. An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc. Natl. Acad. Sci. USA, 93: 7826-7831, 1996.
45. Becker, J. C., Pancook, J. D., Gillies, S. D., Furukawa, K., and Reisfeld, R. A. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J. Exp. Med., 183: 2361-2366, 1996.
46. Becker, J. C., Varki, N., Gillies, S. D., Furukawa, K., and Reisfeld, R. A. Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy. J. Clin. Invest., 98: 2801-2804, 1996.